Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases

[1]  S. Ou,et al.  Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Yi-long Wu,et al.  The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  P. Stephens,et al.  Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  Jeffrey W. Clark,et al.  Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  K. Rex,et al.  In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models , 2016, Molecular Cancer Therapeutics.

[6]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[7]  Lucio Crinò,et al.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[9]  Mark Rosenzweig,et al.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. , 2015, Cancer discovery.

[10]  S. Ou,et al.  Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS. , 2015, Chinese clinical oncology.

[11]  Ruey-min Lee,et al.  Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. , 2014, The Lancet. Oncology.

[12]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[13]  Christopher D. Hart,et al.  Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer , 2013, OncoTargets and therapy.

[14]  J. Graff,et al.  LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models , 2012, Investigational New Drugs.

[15]  Joseph Schoepfer,et al.  A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. , 2011, Cancer research.

[16]  S. Kobayashi,et al.  CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.